Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Lexicon Pharmaceuticals from “strong sell” to “hold.” Analyst views remain mixed overall, with MarketBeat reporting an average “hold” rating and a $5.70 average price target.
• Lexicon’s third-quarter loss was narrower than expected at $0.03 per share, while revenue of $11.25 million exceeded the $4.14 million consensus. The company nevertheless remains unprofitable.
• Clinical developments offer potential future catalysts: the Phase 3 SONATA-HCM trial is overenrolled, with top-line results expected in Q1 2027, and positive STENO1 safety data may support a ZYNQUISTA NDA resubmission.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "strong sell" rating to a "hold" rating in a research note issued on Sunday, Wall Street Zen reports.

Several other equities analysts have also recently weighed in on the company. Cantor Fitzgerald assumed coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an "overweight" rating and a $8.00 price objective on the stock. Zacks Research lowered Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.70.

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock opened at $1.78 on Friday. The stock's fifty day simple moving average is $1.81 and its 200 day simple moving average is $1.89. The company has a current ratio of 13.37, a quick ratio of 13.29 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $792.03 million, a PE ratio of -12.71 and a beta of 1.10. Lexicon Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $2.68.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 35.88% and a negative net margin of 161.80%. The firm had revenue of $11.25 million during the quarter, compared to analysts' expectations of $4.14 million. On average, research analysts predict that Lexicon Pharmaceuticals will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LXRX. Siren L.L.C. boosted its holdings in shares of Lexicon Pharmaceuticals by 13.8% in the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company's stock valued at $69,113,000 after buying an additional 5,384,615 shares during the last quarter. Renaissance Technologies LLC raised its position in Lexicon Pharmaceuticals by 508.0% during the first quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company's stock worth $2,497,000 after acquiring an additional 1,337,246 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Lexicon Pharmaceuticals in the second quarter valued at $1,365,000. Bank of America Corp DE grew its position in shares of Lexicon Pharmaceuticals by 415.3% in the 1st quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company's stock valued at $821,000 after acquiring an additional 424,006 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $1,170,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Key Lexicon Pharmaceuticals News

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Lexicon posted a Q3 loss of $0.03 per share, narrower than the $0.06 loss analysts expected and the $0.04 loss a year earlier. Revenue of $11.25 million also topped estimates of about $4.14 million. Zacks earnings report
• Positive Sentiment: The Phase 3 SONATA-HCM trial is substantially overenrolled, with top-line results expected in Q1 2027. This could provide a significant upcoming clinical catalyst. Lexicon clinical and financial update
• Positive Sentiment: Lexicon said positive STENO1 safety data strengthen the benefit-risk profile for a ZYNQUISTA NDA resubmission, potentially advancing another path to value creation. Lexicon clinical and financial update
• Neutral Sentiment: Phase 1 clinical development of LX9851 is ongoing at Novo Nordisk; the update indicates continued progress but offered no new results or specific timeline. Lexicon clinical and financial update
• Negative Sentiment: Despite beating estimates, Lexicon still reported a quarterly loss, reflecting continued profitability risk as investors await clinical and regulatory progress.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon's commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.